Introduction: The outcome of patients with metastatic, progressive or recurrent neuroendocrine tumors remains poor despite the several novel therapeutic approaches.
Aim(s): To assess contribution of experimental bio-differentiating and antiangiogenic therapy with GEP-NET patients, along with metronomic application of chemotherapy, after failure of any form of oncological therapy available.
Materials and methods: Therapy according to the COMBAT schema was started with 12 patients (eight men and four women), median age 62 years. Such a therapeutic schema is based on combination of peroral antiangiogenic doses of celecoxib and fenofibrate, along with metronomic doses of chemotherapeutics (cyclophosphamide and temozolomide), together with pro-differentiating character of vitamin D /25 OH D(3), 1-25 OH D(3). Further, tumor markers of chromogranin A, NSE, TPS, and TK were assessed.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Others
Presenting Author: MD Lubos Holubec
To read results and conclusion, please login ...
Further abstracts you may be interested in